—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Exelixis Inc (EXEL) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for EXEL, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.90 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How EXEL has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.90 — moves strongly with bonds for every 1% move in TLT (20+ year Treasuries), Exelixis Inc moved 0.90% on average · correlation 0.23 · higher than 83% of US names
  • Beta, last 3 months 1.19 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.65% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +2.15% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against EXEL on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Exelixis Inc

EXEL in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Exelixis is an oncology company that discovers, develops and sells medicines for hard-to-treat cancers, mainly in the United States. Its main product, CABOMETYX, treats advanced renal cell carcinoma after prior anti-angiogenic therapy, while COMETRIQ addresses progressive medullary thyroid cancer; both derive from cabozantinib, a multi-target kinase inhibitor. COTELLIC, a MEK inhibitor, is combined with other drugs for advanced melanoma, and MINNEBRO treats hypertension in Japan. The company also runs an early pipeline of kinase and antibody-drug-conjugate candidates, including zanzalintinib, often through collaborations with larger pharmaceutical partners such as Roche, Takeda and Bristol-Myers Squibb.
Where it sits in the stack
Exelixis carries no seat in our Rubin AI build-out index. It sits in the healthcare sector, within the biotechnology sleeve of our wider universe, tracked by the diary as a drug-development name outside the AI stack.
Who it is priced against
The diary has no peer group set for Exelixis in this instance; it operates among oncology-focused biotechnology firms, and the wider market often names Bristol-Myers Squibb as a comparable oncology drugmaker.
Why Closelooknet tracks it
Exelixis holds a seat in the Russell 1000. It does not yet carry a Closelooknet score, and the diary has not recorded any quotes or editions for it so far.
What the diary watches
The diary watches how sales of CABOMETYX hold up as other firms target the same anti-angiogenic pathway, and how early pipeline candidates such as zanzalintinib move through trials.

Exelixis Inc (EXEL) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 2 analyst actions on the wire · latest: price target by Market Perform into patent cliff, 2026-08-18

The Street on this name

Analyst actions and the latest print for EXEL from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Market Perform into patent cliff — target 54 Target set to $54 (+1.7% to spot) 2026-08-18
  • Initiation BMO Capital — at Market Perform Initiated to Market Perform from Market Perform 2026-08-18

2 actions on the analyst wire since 2026-08-13: 1 initiation, 1 target change. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Exelixis Inc (EXEL)?

Exelixis Inc trades as EXEL on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is EXEL in a Closelooknet index?

Not currently — Exelixis Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does EXEL trade against its moving averages?

Uptrend stack intact: Trades +4.7% vs the 50-day and +19.5% vs the 200-day average, 2.6% below the 52-week high and +72.3% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Exelixis Inc trade when bond yields rise?

Over the past year Exelixis Inc had a beta of 0.90 to TLT, the long-dated Treasury fund — it moves strongly with bonds, higher than 83% of US names. On the 10 sessions in which long bonds fell most it moved −0.65% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Exelixis Inc do?

Exelixis is an oncology company that discovers, develops and sells medicines for hard-to-treat cancers, mainly in the United States. Its main product, CABOMETYX, treats advanced renal cell carcinoma after prior anti-angiogenic therapy, while COMETRIQ addresses progressive medullary thyroid cancer; both derive from cabozantinib, a multi-target kinase inhibitor. COTELLIC, a MEK inhibitor, is combined with other drugs for advanced melanoma, and MINNEBRO treats hypertension in Japan. The diary has no peer group set for Exelixis in this instance; it operates among oncology-focused biotechnology firms, and the wider market often names Bristol-Myers Squibb as a comparable oncology drugmaker.

Where does Exelixis Inc sit in the AI build-out?

Exelixis carries no seat in our Rubin AI build-out index. It sits in the healthcare sector, within the biotechnology sleeve of our wider universe, tracked by the diary as a drug-development name outside the AI stack. Exelixis holds a seat in the Russell 1000. It does not yet carry a Closelooknet score, and the diary has not recorded any quotes or editions for it so far.

What has Wall Street done on Exelixis Inc recently?

The most recent analyst action on Exelixis Inc on the Closelooknet wire is a price target by Market Perform into patent cliff on 2026-08-18 (target 54). 2 actions on the analyst wire since 2026-08-13: 1 initiation, 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for EXEL, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.